Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

MTS withdrew from MTS Live Arena" concert project

2/22/23 MTSS

Nornickel updates mid-term development plans by the end of the year

2/22/23 GMKN

Aimco reported for 2022

2/22/23 AIV

Investment company BDT Capital Partners bought Weber

2/21/23 WEBR

The Home Depot announced a quarterly dividend

2/21/23 HD

Walmart reported for fiscal year 2023

2/21/23 WMT

Home Depot reported for 2022

2/21/23 HD

Polyus will reconsider the terms of the feasibility study project at Sukhoy Log deposit

2/21/23 PLZL

SUAL Partners demands justification of Rusal's purchase of RusHydro shares

2/21/23 RUAL

Polyus produced 6% less gold in 2022

2/21/23 PLZL